help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HOSHIKAWA, Y.
Right arrow Articles by GERACI, M. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HOSHIKAWA, Y.
Right arrow Articles by GERACI, M. W.

Am. J. Respir. Crit. Care Med., Volume 164, Number 2, July 2001, 314-318

Prostacyclin Receptor-dependent Modulation of Pulmonary Vascular Remodeling

YASUSHI HOSHIKAWA, NORBERT F. VOELKEL, TRACY L. GESELL, MARK D. MOORE, KENNETH G. MORRIS, LORI A. ALGER, SHUH NARUMIYA, and MARK W. GERACI

Division of Pulmonary Sciences and Critical Care Medicine, Cardiovascular Pulmonary Research Laboratory, University of Colorado Health Sciences Center, Denver, Colorado; and Department of Pharmacology, Kyoto University, Sakyo, Kyoto, Japan

Prostacyclin (PGI2) reduces pulmonary vascular resistance and attenuates vascular smooth muscle cell proliferation through signal transduction following ligand binding to its receptor. Because patients with severe pulmonary hypertension have a reduced PGI2 receptor (PGI-R) expression in the remodeled pulmonary arterial smooth muscle, we hypothesized that pulmonary vascular remodeling may be modified PGI-R dependently. To test this hypothesis, PGI-R knockout (KO) and wild-type (WT) mice were subjected to a simulated altitude of 17,000 ft or Denver altitude for 3 wk, and right ventricular pressure and lung histology were assessed. The PGI-R KO mice developed more severe pulmonary hypertension and vascular remodeling after chronic hypoxic exposure when compared to the WT mice. Our results indicate that PGI2 and its receptor play an important role in the regulation of hypoxia-induced pulmonary vascular remodeling, and that the absence of a functional receptor worsens pulmonary hypertension.

Key Words: knockout mice; prostacyclin receptor; pulmonary hypertension; chronic hypoxia




This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
N. W. Morrell, S. Adnot, S. L. Archer, J. Dupuis, P. Lloyd Jones, M. R. MacLean, I. F. McMurtry, K. R. Stenmark, P. A. Thistlethwaite, N. Weissmann, et al.
Cellular and molecular basis of pulmonary arterial hypertension.
J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S20 - S31.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
R. Nemenoff, A. M. Meyer, T. M. Hudish, A. B. Mozer, A. Snee, S. Narumiya, R. S. Stearman, R. A. Winn, M. Weiser-Evans, M. W. Geraci, et al.
Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator-Activated Receptor {gamma}
Cancer Prevention Research, October 1, 2008; 1(5): 349 - 356.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Kuwano, A. Hashino, K. Noda, K. Kosugi, and K. Kuwabara
A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic Acid (MRE-269), on Rat Pulmonary Artery
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 691 - 699.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Y.-J. Lai, S. S. Pullamsetti, E. Dony, N. Weissmann, G. Butrous, G.-A. Banat, H. A. Ghofrani, W. Seeger, F. Grimminger, and R. T. Schermuly
Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 188 - 196.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice
FASEB J, June 1, 2008; 22(6): 1849 - 1860.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. E. Fredenburgh, O. D. Liang, A. A. Macias, T. R. Polte, X. Liu, D. F. Riascos, S. W. Chung, S. L. Schissel, D. E. Ingber, S. A. Mitsialis, et al.
Absence of Cyclooxygenase-2 Exacerbates Hypoxia-Induced Pulmonary Hypertension and Enhances Contractility of Vascular Smooth Muscle Cells
Circulation, April 22, 2008; 117(16): 2114 - 2122.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. I. Said
Mediators and modulators of pulmonary arterial hypertension
Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L547 - L558.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. M. Littler, C. A. Wehling, M. J. Wick, K. A. Fagan, C. D. Cool, R. O. Messing, and E. C. Dempsey
Divergent contractile and structural responses of the murine PKC-{epsilon} null pulmonary circulation to chronic hypoxia
Am J Physiol Lung Cell Mol Physiol, December 1, 2005; 289(6): L1083 - L1093.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J L Wright, R D Levy, and A Churg
Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment
Thorax, July 1, 2005; 60(7): 605 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. K. K. Sheares, T. K. Jeffery, L. Long, X. Yang, and N. W. Morrell
Differential effects of TGF-{beta}1 and BMP-4 on the hypoxic induction of cyclooxygenase-2 in human pulmonary artery smooth muscle cells
Am J Physiol Lung Cell Mol Physiol, November 1, 2004; 287(5): L919 - L927.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
R. H. Ritchie, A. C. Rosenkranz, L. P. Huynh, T. Stephenson, D. M. Kaye, and G. J. Dusting
Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling
Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1179 - H1185.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. Budhiraja, R. M. Tuder, and P. M. Hassoun
Endothelial Dysfunction in Pulmonary Hypertension
Circulation, January 20, 2004; 109(2): 159 - 165.
[Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
Y. Hoshikawa, P. Nana-Sinkam, M. D. Moore, S. Sotto-Santiago, T. Phang, R. L. Keith, K. G. Morris, T. Kondo, R. M. Tuder, N. F. Voelkel, et al.
Hypoxia induces different genes in the lungs of rats compared with mice
Physiol Genomics, February 6, 2003; 12(3): 209 - 219.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Compliance (COMmunicate PLease wIth Less Abbreviations, Noun Clusters, and Exclusiveness)
Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1534 - 1536.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. M. Miggin and B. T. Kinsella
Investigation of the Mechanisms of G Protein: Effector Coupling by the Human and Mouse Prostacyclin Receptors. IDENTIFICATION OF CRITICAL SPECIES-DEPENDENT DIFFERENCES
J. Biol. Chem., July 19, 2002; 277(30): 27053 - 27064.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2001
Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 642 - 662.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. M. Tuder and A. L. Zaiman
Prostacyclin Analogs as the Brakes for Pulmonary Artery Smooth Muscle Cell Proliferation . Is It Sufficient to Treat Severe Pulmonary Hypertension?
Am. J. Respir. Cell Mol. Biol., February 1, 2002; 26(2): 171 - 174.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2001 American Thoracic Society 		  ATS Par News